Followers | 5 |
Posts | 605 |
Boards Moderated | 0 |
Alias Born | 07/14/2024 |

Sunday, April 20, 2025 2:02:51 PM
1. Control First: By acquiring 54% of TWOH’s common shares, Assentato gains effective control—enabling him to set direction without resistance from legacy shareholders or management.
2. Strategic Pivot: At NUKK, he shifted the company’s focus to a fintech-oriented business. With TWOH, he may aim to do the same—pivoting to a more promising sector with potential for investor interest.
3. Attract Partnerships & Capital: He brings credibility from his time in investment banking and fintech, which could help TWOH attract partnerships, institutional interest, or private placements.
4. Leverage Public Shell for Growth: Just like NUKK, TWOH may be used as a vehicle for acquisitions, mergers, or product launches that benefit from the public listing.
5. Value Creation & Liquidity: His end goal may be to increase shareholder value through a narrative transformation and potentially uplist to a more reputable exchange, which could lead to liquidity events or monetization for early stakeholders.
In short: Based on his NUKK playbook, Assentato likely sees TWOH as an underutilized vehicle he can reshape into something valuable—leveraging his experience in finance, turnarounds, and growth sectors to drive the transformation.
Recent TWOH News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 09:13:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2025 04:14:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/02/2025 08:43:22 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/14/2025 08:58:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2025 07:32:06 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2025 12:35:31 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/14/2025 06:44:17 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/14/2025 06:43:35 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/28/2025 11:12:00 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/24/2025 01:19:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2025 04:13:35 PM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 01/10/2025 04:09:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/30/2024 09:12:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/18/2024 10:18:48 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2024 09:03:41 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM